Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | HTR7 | P34969 | 5/20 | 0.36 |
| ▸ | HTR6 | P50406 | 5/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | DNM2 | P50570 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274458 | 1.00 | HTR1A (0.36) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL9621722 | 1.00 | HTR1A (0.36) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL2534130 | 0.98 | NPY1R (0.36) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL1274425 | 0.91 | HRH3 (0.37) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL25434244 | 0.87 | SLC29A1 (0.49) | TLR8SLC29A1DNM2 | |
| SCHEMBL11293174 | 0.87 | SLC29A1 (0.49) | TLR8SLC29A1DNM2 | |
| SCHEMBL21585426 | 0.82 | HSP90AA1 (0.36) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL4163258 | 0.82 | TLR8 (0.46) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL3809514 | 0.82 | HTR7 (0.47) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL4161007 | 0.82 | HTR7 (0.47) | HTR1ADRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12010996-B2 | Tris-substituted biguanide compounds and their uses | CHEN HWANG HSING (US) | 2024-06-18 | — | — | US | claimed |
| US-20220015366-A1 | TRIS-SUBSTITUTED BIGUANIDE COMPOUNDS AND THEIR USES | CHEN HWANG HSING (US) | 2022-01-20 | — | — | US | claimed |
| US-20190373895-A1 | BRANCHED POLYMERIC BIGUANIDE COMPOUNDS AND THEIR USES | CHEN HWANG HSING (US) | 2019-12-12 | — | — | US | claimed |
| US-12010996-B2 | Tris-substituted biguanide compounds and their uses | CHEN HWANG HSING (US) | 2024-06-18 | — | — | US | disclosed |
| CN-114957658-B | Polycondensation type thermosetting resin prepolymer and application method thereof | 西南林业大学 | 2023-02-24 | — | — | CN | disclosed |
| CN-114957658-A | Polycondensation type thermosetting resin prepolymer and application method thereof | 西南林业大学 | 2022-08-30 | — | — | CN | disclosed |
| US-20220015366-A1 | TRIS-SUBSTITUTED BIGUANIDE COMPOUNDS AND THEIR USES | CHEN HWANG HSING (US) | 2022-01-20 | — | — | US | disclosed |
| US-11044912-B2 | Branched polymeric biguanide compounds and their uses | CHEN HWANG HSING (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190373895-A1 | BRANCHED POLYMERIC BIGUANIDE COMPOUNDS AND THEIR USES | CHEN HWANG HSING (US) | 2019-12-12 | — | — | US | disclosed |
| EP-1023398-B1 | STABLE WATERBORNE POLYMER COMPOSITIONS CONTAINING POLY(ALKYLENEIMINES) | EASTMAN CHEM CO (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1140866-A1 | TAHM/PIBMALA DISPERSANTS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2001-10-10 | — | — | EP | disclosed |
| US-6284717-B1 | REACTION PRODUCT OF A MODIFIED POLYOLEFIN AND TRIAMINOTRIAZOLE COMPOUND | INFINEUM USA L.P. | 2001-09-04 | — | — | US | disclosed |
| WO-2000037449-A1 | TAHM/PIBMALA DISPERSANTS | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2000-06-29 | — | — | WO | disclosed |
| EP-0510117-A4 | MODIFIED POLYOXYETHYLENE EPOXY RESIN AMPHIPHILES AND STABLE AQUEOUS EPOXY DISPERSIONS THEREOF | — | 1993-02-03 | — | — | EP | disclosed |
| EP-0510117-A1 | MODIFIED POLYOXYETHYLENE EPOXY RESIN AMPHIPHILES AND STABLE AQUEOUS EPOXY DISPERSIONS THEREOF | THE DOW CHEMICAL COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| EP-0496163-A1 | Stable amine advanced epoxy resin compositions | THE DOW CHEMICAL COMPANY (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0491550-A2 | Water-emulsifiable epoxy resin composition | THE DOW CHEMICAL COMPANY (US) | 1992-06-24 | — | — | EP | disclosed |
| EP-0240867-B1 | PROCESS FOR THE PREPARATION OF AMINOALKYL- OR -ARYLMELAMINES | BASF Aktiengesellschaft (DE) | 1992-02-19 | — | — | EP | disclosed |
| WO-1991010695-A1 | MODIFIED POLYOXYETHYLENE EPOXY RESIN AMPHIPHILES AND STABLE AQUEOUS EPOXY DISPERSIONS THEREOF | THE DOW CHEMICAL COMPANY (US) | 1991-07-25 | — | — | WO | disclosed |
| EP-0240867-A1 | Process for the preparation of aminoalkyl- or -arylmelamines | BASF Aktiengesellschaft (DE) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11044912-B2 | Branched polymeric biguanide compounds and their uses | PUF60, XRCC6, PCNA | HTR1A 4174/4885DRD2 463/4885HTR2A 1690/4885 |
| US-20220015366-A1 | TRIS-SUBSTITUTED BIGUANIDE COMPOUNDS AND THEIR USES | PUF60, KCNN1, XRCC6 | HTR1A 4778/4885DRD2 1081/4885HTR2A 4322/4885 |
| US-12010996-B2 | Tris-substituted biguanide compounds and their uses | PUF60, KCNN1, XRCC6 | HTR1A 4778/4885DRD2 1081/4885HTR2A 4322/4885 |
| US-20190373895-A1 | BRANCHED POLYMERIC BIGUANIDE COMPOUNDS AND THEIR USES | PUF60, XRCC6, PCNA | HTR1A 4174/4885DRD2 463/4885HTR2A 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.